Activity of Ceftaroline against Recent Emerging Serotypes of Streptococcus pneumoniae in the United States

被引：59

作者：

Jacobs, Michael R. ^{[1
,2
]}

Good, Caryn E. ^{[1
,2
]}

Windau, Anne R. ^{[1
,2
]}

Bajaksouzian, Saralee ^{[1
,2
]}

Biek, Donald ^{[3
]}

Critchley, Ian A. ^{[3
]}

Sader, Helio S. ^{[4
]}

Jones, Ronald N. ^{[4
]}

机构：

[1] Case Western Reserve Univ, Cleveland, OH 44106 USA

[2] Univ Hosp, Case Med Ctr, Cleveland, OH USA

[3] Cerexa Inc, Oakland, CA USA

[4] JMI Labs, N Liberty, IA USA

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2010年 / 54卷 / 06期

关键词：

CONJUGATE VACCINE; METHICILLIN-RESISTANT; STAPHYLOCOCCUS-AUREUS; PNEUMOCOCCAL DISEASE; CEPHALOSPORIN; EMERGENCE; 19A; COLLECTION; CLEVELAND; PPI-0903;

D O I：

10.1128/AAC.01797-09

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

The in vitro activity of ceftaroline against 891 pneumococci collected in 2008 from 22 centers in the United States was investigated. Ceftaroline was the most potent agent tested, with the MICs being <0.008 to 0.5 mu g/ml and the MIC(90)s being <0.008 to 0.25 mu g/ml against 11 prevailing serotypes. The overall rates of susceptibility were as follows: penicillin G, 86.2%; ceftriaxone, 90.7%; cefuroxime, 70.1%; erythromycin, 61.6%; clindamycin, 79.2%; levofloxacin, 99.4%; and vancomycin, 100%. Serotype 19A isolates were the least susceptible. These results support the use of ceftaroline for the treatment of pneumococcal infections, including those caused by pneumococci resistant to other agents.

引用

页码：2716 / 2719

页数：4

共 25 条

[1] Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models:: Identification of an in vivo pharmacokinetic-pharmacodynamic target [J].

Andes, D ;

Craig, WA .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (04) :1376-1383

[2]

[Anonymous], 46 INT C ANT AG CHEM

[3]

[Anonymous], 2009, 49 INT C ANT AG CHEM

[4]

Clinical and Laboratory Standards Institute, 2009, M7A8 CLIN LAB STAND

[5]

Clinical and Laboratory Standards Institute, 2009, M100S19 CLSI S

[6]

COREY R, 2008, 48 ANN INT C ANT AG

[7] In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States [J].

Ge, Yigong ;

Biek, Donald ;

Talbot, George H. ;

Sahm, Daniel F. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2008, 52 (09) :3398-3407

[8] Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the united states during the era of widespread PCV7 vaccination, 1998-2004 [J].

Hicks, Lauri A. ;

Harrison, Lee H. ;

Flannery, Brendan ;

Hadler, James L. ;

Schaffner, William ;

Craig, Allen S. ;

Jackson, Delois ;

Thomas, Ann ;

Beall, Bernard ;

Lynfield, Ruth ;

Reingold, Arthur ;

Farley, Monica M. ;

Whitney, Cynthia G. .

JOURNAL OF INFECTIOUS DISEASES, 2007, 196 (09) :1346-1354

[9] Emergence of Streptococcus pneumoniae Serotypes 19A, 6C, and 22F and Serogroup 15 in Cleveland, Ohio, in Relation to Introduction of the Protein-Conjugated Pneumococcal Vaccine [J].

Jacobs, Michael R. ;

Good, Caryn E. ;

Bajaksouzian, Saralee ;

Windau, Anne R. .

CLINICAL INFECTIOUS DISEASES, 2008, 47 (11) :1388-1395

[10] Changes in serotypes and antimicrobial susceptibility of invasive Streptococcus pneumoniae strains in Cleveland:: a quarter century of experience [J].

Jacobs, Michael R. ;

Good, Caryn E. ;

Beall, Bernard ;

Bajaksouzian, Saralee ;

Windau, Anne R. ;

Whitney, Cynthia G. .

JOURNAL OF CLINICAL MICROBIOLOGY, 2008, 46 (03) :982-990

← 1 2 3 →